Related Experiment Video

Updated: May 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K

Review Article: Efficacy and Safety of JNK Inhibitors in Cancer Therapy

Lakkakula Suhasini Sahithi1, Poojith Nuthalapati2, Mohammed Faiz Hussain3

  • 1Department of Biotechnology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India.

Critical Reviews in Oncogenesis
|November 23, 2025
PubMed

Insights

C-Jun N-terminal protein kinases (JNKs) are crucial in cancer cell survival and progression. This review explores new JNK inhibitors as potential cancer therapeutics, targeting aberrant JNK signaling in tumors.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • C-Jun N-terminal protein kinases (JNKs), part of the MAPK family, regulate critical cellular processes including proliferation, survival, and apoptosis.
  • Aberrant JNK signaling is implicated in the development and progression of various cancers, influencing cancer cell death and survival.
  • JNKs represent promising therapeutic targets due to their dysregulation in numerous malignancies.

Purpose of the Study:

  • To review the development of novel JNK inhibitors for cancer treatment.
  • To enhance the understanding of JNK signaling pathways in cancer progression.
  • To highlight the therapeutic potential of targeting JNK in oncology.

Main Methods:

  • Literature review of studies on JNK signaling in cancer.
  • Analysis of research on the development and efficacy of JNK inhibitors.
  • Synthesis of information on JNK's role in tumorigenesis and cancer cell fate.

Main Results:

  • JNK signaling pathways are significantly involved in cancer cell proliferation, survival, and apoptosis.
  • Dysregulated JNK activity is a common feature across many types of cancer.
  • Development of specific JNK inhibitors is a key focus in current cancer therapeutic research.

Conclusions:

  • JNK inhibitors hold significant promise as targeted therapies for various cancers.
  • Targeting JNK signaling can modulate cancer cell survival and potentially induce tumor cell death.
  • Further research into JNK inhibitors is essential for advancing cancer treatment strategies.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.1K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...